Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-02-2015 | Original Article – Cancer Research

ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens

Authors: Jinguo Liu, Ruiying Zhao, Jie Zhang, Jian Zhang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2015

Abstract

Purpose

Epidermal growth factor receptor (EGFR) mutation analysis is becoming a routine clinical practice for lung adenocarcinoma patients. Most patients with lung cancer are diagnosed at an advanced stage of the disease and are not suitable for surgical therapy. In many cases, cytologic specimens may be the only tissue available for diagnostic and molecular testing. Therefore, it is important to determine what condition the cytologic specimens should be in for adequately analyzing EGFR mutation status.

Methods

Fifty-eight paired cytologic and lung adenocarcinoma histologic specimens that satisfied 3 requisite parameters (>2 ng/μl DNA concentration, >30 tumor cells content, and >25 % tumor percentage) were collected. Exons 18 through 21 of the EGFR gene were analyzed by amplification refractory mutations system.

Results

The EGFR mutation concordance rate between cytologic specimens and corresponding histologic specimens was 100 %. A set of 30 paired specimens from different sites (lung and pleural fluids) from the same patient exhibited 100 % concordance in the EGFR mutation analysis results.

Conclusions

In this study, EGFR mutation presented a convenient and reliable method for the analysis of cytologic specimens that satisfied 3 requisite parameters (>2 ng/μl DNA concentration, >30 tumor cells content, and >25 % tumor percentage). We concluded that the specimens from both primary lung adenocarcinomas and metastatic lesions (such as pleural fluids) can be used for EGFR mutation analysis.

Aisner DL, Deshpande C, Baloch Z, Watt CD, Litzky LA, Malhotra B et al (2013) Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol 41:316–323PubMedCrossRef

Boyle P, Levin B (2008) World cancer report 2008. International Agency for Research on Cancer, Lyon

Bruno P, Mariotta S, Ricci A, Duranti E, Scozzi D, Noto A et al (2011) Reliability of direct sequencing of EGFR: comparison between cytological and histological samples from the same patient. Anticancer Res 31:4207–4210PubMed

Chowdhuri SR, Xi L, Pham TH, Hanson J, Rodriguez-Canales J, Berman A et al (2012) EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 25:548–555PubMedCrossRef

Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M et al (2007) Cancer incidence in five continents, vol IX. IARC Scientific Publications, Lyon

D’Angelo SP, Park B, Azzoli CG, Kris MG, Rusch V, Ladanyi M et al (2011a) Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg 141:476–480PubMedCrossRef

D’Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS et al (2011b) Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29:2066–2070PubMedCentralPubMedCrossRef

da Cunha Santos G, Saieg MA, Geddie W, Leighl N (2011) EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 119:80–91CrossRef

Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J et al (2010) A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 29:132PubMedCentralPubMedCrossRef

Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC et al (2012) Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 39:366–372PubMedCrossRef

Gupta R, Dastane AM, Forozan F, Riley-Portuguez A, Chung F, Lopategui J et al (2009) Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol 22:128–133PubMedCrossRef

Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY et al (2011) EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 12:380–386PubMedCrossRef

Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V et al (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99:923–929PubMedCentralPubMedCrossRef

Khode R, Larsen DA, Culbreath BC, Parrish S, Walker KL, Sayage-Rabie L et al (2013) Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol 121:361–369PubMedCrossRef

Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B et al (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915–3921PubMedCrossRef

Ladanyi M, Pao W (2008) Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21:S16–S22PubMedCrossRef

Malapelle U, de Rosa N, Rocco D, Bellevicine C, Crispino C, Illiano A et al (2012) EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol 65:87–91PubMedCrossRef

Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V et al (2012) Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med 185:1316–1322PubMedCentralPubMedCrossRef

Pao W, Ladanyi M (2007) Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13:4954–4955PubMedCrossRef

Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA et al (2011) Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6:28–31PubMedCentralPubMedCrossRef

Savic S, Tapia C, Grilli B, Rufle A, Bihl MP, de Vito Barascud A et al (2008) Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 98:154–160PubMedCentralPubMedCrossRef

Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG (2006) The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer. J Thorac Oncol 1:324–327PubMedCrossRef

Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI (2009) EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 117:67–72PubMed

Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B (2011) Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res 30:30PubMedCentralPubMedCrossRef

Sun PL, Jin Y, Kim H, Lee CT, Jheon S, Chung JH (2013) High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. Cancer Cytopathol 121:311–319PubMedCrossRef

Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A et al (2007) Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 98:246–252PubMedCrossRef

Yatabe Y, Matsuo K, Mitsudomi T (2011) Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29:2972–2977PubMedCrossRef

Title: ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens
Authors: Jinguo Liu
Ruiying Zhao
Jie Zhang
Jian Zhang
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 2/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1807-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest

Lysyl oxidase-like 4 (LOXL4) promotes proliferation and metastasis of gastric cancer via FAK/Src pathway

The biological and clinical importance of epithelial–mesenchymal transition in circulating tumor cells

Protein expression and promoter methylation of the candidate biomarker TCF21 in gastric cancer

Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study

DJ-1: a promising marker in metastatic uveal melanoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials